Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eledon Pharmaceuticals, Inc. (ELDN)
:ELDN
RESEARCH TOOLSreports
ELDN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.52 - $5.54
Previous CloseN/A
Volume121.23K
Average Volume (3M)261.62K
Market Cap
$259.27M
Enterprise Value$60.45M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Mar 27, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.71
Shares Outstanding59,739,277
10 Day Avg. Volume204,186
30 Day Avg. Volume261,620
Standard Deviation0.32
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-161.63
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$9.50Price Target Upside118.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Eledon Pharmaceuticals News
PremiumCompany Announcements
Eledon Pharma Adjusts CEO Bonus Structure
PremiumCompany Announcements
Eledon Pharmaceuticals Reports Strong Q3 2024 Results
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyRecent data from an investigator initiated trial at UChicago Medicine evaluating tego as part of an immunosuppressive regimen to prevent islet cell transplant rejection appear compelling, with the first two subjects treated achieving insulin independence.
Clinical Trial ProgressELDN completed enrollment in BESTOW in September 2024, which was approximately four months ahead of schedule, suggesting an encouraging physician and patient experience to date.
Financial HealthEledon bolstered its balance sheet by successfully raising $85M in a public offering.
Bears Say
---
Ownership Overview
22.46% Insiders
3.28% Mutual Funds
43.04% Other Institutional Investors
25.87% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELDN FAQ
What was Eledon Pharmaceuticals, Inc.’s price range in the past 12 months?
Eledon Pharmaceuticals, Inc. lowest stock price was $1.52 and its highest was $5.54 in the past 12 months.
What is Eledon Pharmaceuticals, Inc.’s market cap?
Eledon Pharmaceuticals, Inc.’s market cap is $259.27M.
When is Eledon Pharmaceuticals, Inc.’s upcoming earnings report date?
Eledon Pharmaceuticals, Inc.’s upcoming earnings report date is Mar 27, 2025 which is in 33 days.
How were Eledon Pharmaceuticals, Inc.’s earnings last quarter?
Eledon Pharmaceuticals, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.315 by -$0.005.
Is Eledon Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Eledon Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Eledon Pharmaceuticals, Inc. pay dividends?
Eledon Pharmaceuticals, Inc. does not currently pay dividends.
What is Eledon Pharmaceuticals, Inc.’s EPS estimate?
Eledon Pharmaceuticals, Inc.’s EPS estimate is -0.31.
How many shares outstanding does Eledon Pharmaceuticals, Inc. have?
Eledon Pharmaceuticals, Inc. has 59,739,277 shares outstanding.
What happened to Eledon Pharmaceuticals, Inc.’s price movement after its last earnings report?
Eledon Pharmaceuticals, Inc. reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.315. Following the earnings report the stock price went down -11.411%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ELDN
---
Eledon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (118.89% Upside)
$9.50 (118.89% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.46%
12-Months-Change
Fundamentals
Return on Equity
-119.41%
Trailing 12-Months
Asset Growth
19.26%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. (Nasdaq:ELDN) is an immunology-focused biotechnology company utilizing its experience in the CD40/CD40L costimulatory pathway to develop and commercialize precision therapies for persons undergoing organ and cellular transplantation, and for people living with autoimmune and neurodegenerative disease. The company’s lead compound in development is tegoprubart (AT-1501), an anti-CD40L antibody. The company, which was established in 2004, is headquartered in Irvine, CA.
---
ELDN Stock 12 Month Forecast
Average Price Target
$9.50
▲(118.89% Upside)
Technical Analysis
X4 Pharmaceuticals
―
Cabaletta Bio
―
Arcutis Biotherapeutics
―
ALX Oncology Holdings
―
Best Analysts Covering ELDN
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+40.42%
reiterated a buy rating 3 months ago
Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +40.42% per trade.
---